OncoEthix Report issue

For profit Phase 1 Phase 2
Founded: Lausanne Switzerland (2007)
Status: Acquired by Merck (2015)

Organization Overview

First Clinical Trial
2012
NCT01724320
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2015

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Oncoethix GmbH

Active Ingredients

Drugs in Phase 2 Trials (2)

azacitidine (vidaza) (1 trial)

birabresib (4 trials)

Drugs in Phase 1 Trials (1)

topomimetic 0118 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adenocarcinoma (Phase 1)

Glioblastoma (Phase 2)

Leukemia (Phase 2)

Leukemia, Myeloid (Phase 2)

Leukemia, Myeloid, Acute (Phase 2)

Lymphoma, Large B-Cell, Diffuse (Phase 1)

Multiple Myeloma (Phase 1)

Neoplasms (Phase 1)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 1)

Triple Negative Breast Neoplasms (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 5
  • # of Trial APIs: 3